Delivery Order 75N93023D00001-75N93023F00003
Award Date
9/1/23
Potential Completion Date
8/31/30
Potential Value
$4.1M
Federal Agency
National Institute of Allergy and Infectious Diseases
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Potomac, MD 20850, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $6,095,159.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL) for expertise in professional pharmaceutical project management. The contract is issued under the larger Resources to Advance Pediatrics and HIV Prevention Science indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL, a manufacturer of biologics including vaccines and monoclonal antibodies,...
This is a federal contract award to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), a civilian federal agency. The contract, valued at $4,328,663.00, is for expertise in the product development lifecycle, including services such as cGMP manufacturing of vaccines and biologics, process development, analytical testing, stability studies, and project management for infectious...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL). The contract, valued at $239,850.00, is a Delivery Order issued under the HIV Microbicides and Biomedical Prevention 2016-2021 master IDIQ vehicle. ABL, a contract research and manufacturing organization, will assist NIAID in planning and implementing two meetings...
This is a definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned, for-profit manufacturer of goods. The contract, valued at $213,045,738.00, is for preclinical development services to support infectious disease research and product development initiatives. The contract does not have a set-aside designation. ABL has been awarded numerous federal contracts and grants,...
This is a $3,500 firm-fixed-price delivery order awarded to Advanced Bioscience Laboratories, Inc. (ABL) by the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. The order is under the NIAID's Diagnostics Pre-Clinical Services Program Indefinite Delivery Vehicle (IDV), which has a total ceiling value of $24 million. ABL, a foreign-owned, for-profit manufacturer, is providing a range of preclinical development services to support...
The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, has awarded a $3,802,507.00 cost-plus-fixed-fee delivery order contract to Advanced Bioscience Laboratories, Inc. (ABL) to provide expertise in using bitter taste receptor blockers to improve the palatability of pediatric medicines. This work is being conducted under the Resources to Advance Pediatrics and HIV Prevention Science indefinite-delivery,...
This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Advanced Bioscience Laboratories, Inc. (ABL). The contract, valued at $835,962.00, is for preclinical development support, specifically the production of the GEO-D02 DNA drug product. This is a cost-plus-fixed-fee delivery order contract with a period of performance ending on February 28, 2022. The contract does not have a...
This federal contract award is to Advanced Bioscience Laboratories, Inc. (ABL) from the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The contract is for the performance of toxicity testing for HIV proteins as part of NIAID's Preclinical Development Support program. The contract is a cost-plus-fixed-fee delivery order with a ceiling value of $1,050,558.51 and a period of performance through April 7, 2017....
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,193,090 cost-plus-fixed-fee delivery order contract to Advanced Bioscience Laboratories, Inc. (ABL) to use artificial intelligence and machine learning to enhance the STEP pediatric excipient database. The contract has an ultimate completion date of July 31, 2025. This delivery order is issued under a larger $98.9 million Indefinite Delivery Vehicle (IDV) contract with NIAID for Resources to Advance Pediatrics and HIV...
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL), a contract research and manufacturing organization. The $3,150,428.64 award is a delivery order under the HIV Microbicides and Biomedical Prevention 2016-2021 indefinite-delivery/indefinite-quantity (IDIQ) contract vehicle. ABL will provide comprehensive resources for HIV...